## Executive Summary & Key Metadata

The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a unique ATP-binding cassette (ABC) transporter that functions as a phosphorylation-regulated, ATP-gated chloride and bicarbonate channel at the apical plasma membrane of epithelial cells. The gene encoding CFTR was identified in 1989 through positional cloning, marking a landmark in human genetics. CFTR is the causative gene for cystic fibrosis (CF), the most common lethal autosomal recessive disorder in populations of Northern European descent, affecting approximately 80,000 individuals worldwide [1]. Beyond classic CF, mutations in CFTR are associated with a spectrum of CFTR-related disorders (CFTR-RDs), including congenital bilateral absence of the vas deferens (CBAVD), idiopathic chronic pancreatitis, and disseminated bronchiectasis [1, 2, 3].

The most common pathogenic variant, F508del (c.1521_1523delCTT; p.Phe508del), is a deletion of a single phenylalanine residue at position 508 in the first nucleotide-binding domain (NBD1). This mutation causes a severe protein folding defect, leading to endoplasmic reticulum-associated degradation (ERAD) of the nascent polypeptide and a near-complete absence of functional CFTR at the cell surface [1, 2, 3]. The F508del folding defect is the central target of modern CFTR modulator therapy, which combines correctors (e.g., lumacaftor, tezacaftor, elexacaftor) to improve folding and trafficking, and potentiators (e.g., ivacaftor) to enhance channel gating [1, 2].

| **Metadata Field** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | CFTR |
| **UniProt Accession** | P13569 |
| **Representative PDB ID** | 5UAK (human CFTR in phosphorylated, ATP-bound, open state) |
| **Chromosomal Locus** | 7q31.2 (GRCh38: chr7:117,480,025-117,668,665) |
| **Primary Molecular Function** | cAMP-dependent chloride (Cl⁻) and bicarbonate (HCO₃⁻) channel; regulator of other ion channels and transporters |
| **Disease & Pathology Associations** | Cystic fibrosis (CF); CFTR-related disorders: CBAVD, idiopathic chronic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), primary sclerosing cholangitis (PSC); modifier of cancer risk (colorectal, pancreatic, lung, prostate) [1, 2, 3] |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Structure

The CFTR gene is located on the long arm of human chromosome 7 at cytogenetic band 7q31.2. The gene spans approximately 189 kilobases (kb) of genomic DNA and comprises 27 exons (numbered 1–24, with exons 6, 14, 17, and 18 split into 6a/6b, 14a/14b, 17a/17b, and 18a/18b, respectively) that encode a mature mRNA of approximately 6.5 kb [1, 2]. The full-length coding sequence is 4,443 nucleotides, translating into a polypeptide of 1,480 amino acids with a predicted molecular mass of ~168 kDa; the mature, glycosylated protein migrates at ~180 kDa on SDS-PAGE [3].

The genomic organization of CFTR is notable for its large intronic regions, which harbor numerous regulatory elements, including DNase I-hypersensitive sites (DHS), enhancers, and silencers. Nuthall et al. (1999) identified several DHS at the 3' end of the gene, suggesting the presence of locus control regions that modulate tissue-specific expression [1]. The promoter region lacks a canonical TATA box but contains an initiator (Inr) sequence and multiple GC boxes, consistent with a housekeeping-like promoter that is nonetheless tightly regulated in a cell-type-specific manner [2, 3].

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of CFTR spans approximately 200 base pairs upstream of the transcription start site (TSS). Key cis-acting elements include:

- **cAMP Response Element (CRE)**: Located at position -48 relative to the TSS. This element binds the transcription factor CREB (cAMP response element-binding protein) and is essential for basal promoter activity in T84 colon carcinoma cells. Protein kinase A (PKA) activity is required for maximal CFTR transcription, linking cellular cAMP levels directly to CFTR gene expression [1, 3].
- **Inverted CCAAT Box (Y-Box)**: A negative regulatory element bound by the CCAAT displacement protein (CDP/cut homolog). CDP represses CFTR transcription by recruiting histone deacetylases (HDACs), leading to a deacetylated, condensed chromatin state at the promoter [2].
- **SP1 Binding Sites**: Multiple GC-rich motifs that bind the constitutively active transcription factor SP1, contributing to basal transcription [2].
- **Tissue-Specific Enhancers**: Intronic and intergenic enhancer elements, particularly in introns 1, 11, and 17a, have been characterized. A regulatory element in intron 1 was shown to enhance CFTR promoter activity in epithelial cells [3]. DNase I-hypersensitive sites at the 3' end of the gene (DHS 1–4) are associated with enhancer activity in intestinal and respiratory epithelial cells [1].

### 1.3 Alternative Splicing and Isoforms

CFTR undergoes complex alternative splicing that generates multiple mRNA isoforms with distinct functional properties:

- **Exon 9 Skipping (ΔEx9)**: The most extensively characterized splice variant involves skipping of exon 9, which encodes part of the first nucleotide-binding domain (NBD1). This isoform, termed CFTRΔEx9, is expressed at high levels in normal bronchial epithelium and lymphocytes [1, 2]. The protein product lacks a functional NBD1 and does not support cAMP-activated chloride conductance [3]. The efficiency of exon 9 inclusion is modulated by a polymorphic (TG)m(T)n repeat tract in the acceptor splice site of intron 8; longer TG repeats and shorter T tracts promote exon skipping [1].
- **Exon 12 Skipping**: A splice donor site mutation in intron 12 (c.1717-1G>A) leads to aberrant splicing and a truncated, non-functional protein [2].
- **Intron 19 Cryptic Splice Site**: The mutation 3849+10kb C>T creates a novel donor splice site 10 kb into intron 19, leading to the insertion of a cryptic exon and a premature termination codon. Antisense oligonucleotides (ASOs) targeting this cryptic splice site have been shown to correct aberrant splicing and restore functional CFTR expression [3].
- **Intron 6b Splicing Regulatory Element**: A disease-associated mutation in intron 6b disrupts a putative splicing regulatory element, leading to exon skipping and reduced CFTR function [1].

The existence of multiple splice isoforms with varying functional capacities contributes to the phenotypic variability observed in CFTR-related disorders, where residual CFTR activity from alternatively spliced transcripts can modulate disease severity [1, 2, 3].

### 1.4 MicroRNA Regulation

CFTR expression is also regulated at the post-transcriptional level by microRNAs (miRNAs). Several miRNAs have been identified that directly target the CFTR 3' untranslated region (UTR) or coding sequence:

- **miR-101 and miR-494**: These miRNAs synergistically bind to the CFTR 3' UTR and downregulate CFTR expression. Overexpression of these miRNAs reduces CFTR protein levels and chloride channel function [3].
- **miR-145-5p**: This miRNA represses CFTR expression in airway epithelial cells. Peptide nucleic acid (PNA)-based anti-miR-145-5p molecules can enhance CFTR expression in Calu-3 cells, representing a potential therapeutic strategy [1].
- **miR-138**: Targeting of SIN3A by miR-138 indirectly upregulates CFTR expression by relieving transcriptional repression [2].
- **miR-17~92 Cluster**: In CF macrophages, elevated expression of the Mirc1/Mir17-92 cluster negatively regulates autophagy and CFTR function, contributing to the hyperinflammatory phenotype characteristic of CF [3].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CFTR protein is a member of the ATP-binding cassette (ABC) transporter superfamily, but it is the only member that functions as an ion channel rather than a transporter. CFTR is organized into five distinct domains:

1. **N-terminal Lasso Domain (Lasso)**: Residues 1–80. This domain anchors the protein to the membrane and interacts with the first transmembrane domain.
2. **Membrane-Spanning Domain 1 (MSD1)**: Residues 80–380. Comprises six transmembrane α-helices (TM1–TM6) that contribute to the formation of the channel pore.
3. **Nucleotide-Binding Domain 1 (NBD1)**: Residues 380–650. Binds and hydrolyzes ATP; contains the F508 residue.
4. **Regulatory Domain (R Domain)**: Residues 650–850. A unique intrinsically disordered domain containing multiple consensus phosphorylation sites for PKA and protein kinase C (PKC). Phosphorylation of the R domain is required for channel activation.
5. **Membrane-Spanning Domain 2 (MSD2)**: Residues 850–1170. Comprises six transmembrane α-helices (TM7–TM12).
6. **Nucleotide-Binding Domain 2 (NBD2)**: Residues 1170–1430. Binds and hydrolyzes ATP; forms a heterodimer with NBD1.
7. **C-terminal Domain (CTD)**: Residues 1430–1480. Contains a PDZ-binding motif (DTRL) that mediates interactions with scaffolding proteins such as NHERF1/EBP50.

### 2.2 High-Resolution Cryo-EM Structures

The determination of high-resolution cryo-electron microscopy (cryo-EM) structures of human CFTR has revolutionized our understanding of its molecular architecture and gating mechanism. The representative structure PDB: 5UAK corresponds to the phosphorylated, ATP-bound, open state of human CFTR [1]. Key structural features revealed by these studies include:

- **Domain-Swapped Architecture**: The two MSDs are arranged in a domain-swapped configuration, with TM1–TM2 from MSD1 interacting with TM11–TM12 from MSD2 to form the channel pore.
- **Ion Permeation Pathway**: The channel pore is lined by residues from TM1, TM3, TM6, TM8, TM10, and TM12. The narrowest point of the pore, the selectivity filter, is formed by the convergence of TM6 and TM12, with the side chains of F337 and T338 contributing to anion selectivity.
- **NBD Dimerization**: ATP binding at the NBD1-NBD2 interface promotes dimerization of the two NBDs, which is coupled to opening of the channel gate. The ATP molecules are sandwiched between the Walker A motif of one NBD and the LSGGQ signature motif of the other.
- **R Domain Positioning**: In the dephosphorylated state, the R domain occupies a position that sterically hinders NBD dimerization. Phosphorylation of the R domain by PKA induces a conformational change that displaces the R domain, allowing NBD dimerization and channel opening.

### 2.3 The F508del Folding Defect

The F508 residue is located in the NBD1 domain, at the surface that interfaces with the intracellular loop 4 (ICL4) of MSD2. The deletion of this phenylalanine residue disrupts the NBD1-ICL4 interaction, which is critical for the proper folding and assembly of the full-length protein. The consequences of F508del are multifaceted:

- **Thermodynamic Destabilization**: The F508del mutation reduces the thermal stability of NBD1 by approximately 2–4 kcal/mol, leading to a partially unfolded state that is recognized by the ER quality control machinery [2].
- **ERAD and Proteasomal Degradation**: The misfolded ΔF508-CFTR is retained in the ER and targeted for ubiquitin-mediated proteasomal degradation. Key E3 ubiquitin ligases involved in this process include CHIP (STUB1), RNF185, and the SYVN1/NEDD8/FBXO2 pathway [2, 3].
- **Peripheral Quality Control**: Even when ΔF508-CFTR is rescued to the plasma membrane by low-temperature incubation or pharmacological correctors, it exhibits a short half-life due to accelerated endocytosis and lysosomal degradation. This process is mediated by clathrin-dependent endocytosis and involves the ubiquitin ligase c-Cbl [2].
- **Keratin Network Involvement**: The intermediate filament protein keratin 18 (K18) interacts with ΔF508-CFTR and modulates its trafficking. Curcumin, a natural compound, can partially rescue ΔF508-CFTR function by modulating the keratin network [1].

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load CFTR (PDB: 5UAK)](/tools/protein-structure-viewer?source=direct&pdbId=5UAK)

The interactive visualizer allows users to explore the three-dimensional structure of CFTR in its phosphorylated, ATP-bound open state. Users can highlight individual domains (MSD1, MSD2, NBD1, NBD2, R domain), locate the F508 residue, and visualize the ATP molecules bound at the NBD dimer interface.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ion Channel Function

CFTR is a cAMP-dependent, ATP-gated chloride channel. The primary function of CFTR is to mediate the transepithelial movement of chloride ions, which drives fluid secretion and absorption across epithelial tissues. CFTR also conducts bicarbonate (HCO₃⁻) ions, which is critical for maintaining the pH of airway surface liquid, pancreatic juice, and bile [2, 3].

The channel is activated by a two-step mechanism:

1. **Phosphorylation**: Binding of a ligand (e.g., a hormone or neurotransmitter) to a G-protein-coupled receptor (GPCR) activates adenylyl cyclase, increasing intracellular cAMP levels. cAMP binds to the regulatory subunits of PKA, releasing the catalytic subunits, which then phosphorylate multiple serine residues in the R domain of CFTR. Phosphorylation of the R domain induces a conformational change that relieves its inhibitory effect on channel gating [1, 3].
2. **ATP Binding and Hydrolysis**: Following phosphorylation, ATP binds to the NBD1 and NBD2 domains. ATP binding at the NBD1-NBD2 interface promotes dimerization, which is coupled to opening of the channel pore. ATP hydrolysis at NBD2 provides the energy for channel closure, resetting the channel to its closed state.

### 3.2 Regulation of Other Ion Channels and Transporters

Beyond its intrinsic channel activity, CFTR functions as a master regulator of other ion transport proteins, forming macromolecular complexes at the apical plasma membrane:

- **Epithelial Sodium Channel (ENaC)**: CFTR negatively regulates ENaC activity. In CF, the loss of CFTR leads to hyperabsorption of sodium and water, contributing to the dehydration of airway surface liquid and impaired mucociliary clearance.
- **Outwardly Rectifying Chloride Channel (ORCC)**: CFTR regulates the activity of ORCC through an autocrine mechanism involving ATP release.
- **SLC26A3 and SLC26A6 (DRA and PAT1)**: CFTR interacts with these bicarbonate/chloride exchangers via PDZ-domain scaffolding proteins, coordinating chloride and bicarbonate secretion.
- **Aquaporins**: CFTR modulates the membrane expression and activity of aquaporin water channels.

### 3.3 The Mirc1/Mir17-92 Cluster and Autophagy

Recent research has uncovered a critical link between CFTR dysfunction and autophagy. In CF macrophages, the expression of the Mirc1/Mir17-92 miRNA cluster is elevated. This cluster negatively regulates autophagy by targeting key autophagy-related genes, including ATG5 and ATG7. The resulting impairment of autophagy leads to the accumulation of damaged mitochondria and increased production of reactive oxygen species (ROS), which in turn exacerbates the hyperinflammatory phenotype of CF macrophages [3]. This pathway represents a potential therapeutic target for modulating the inflammatory response in CF.

### 3.4 CFTR and the Inflammatory Response

CFTR dysfunction is associated with a dysregulated inflammatory response, characterized by excessive neutrophil infiltration and elevated levels of pro-inflammatory cytokines such as IL-8. Monocytes from individuals heterozygous for the ΔF508 mutation exhibit altered IL-8 secretion, suggesting that even carriers of a single CFTR mutation have subtle defects in immune function [1]. CFTR mutations also cause a monocyte-selective adhesion deficiency, impairing the ability of monocytes to adhere to and migrate across the endothelium [2].

### 3.5 Protein-Protein Interaction Networks

CFTR interacts with a large network of proteins that regulate its folding, trafficking, gating, and stability. Key interaction partners include:

- **PDZ-Domain Scaffolding Proteins**: NHERF1 (EBP50), NHERF2, and PDZK1 bind to the C-terminal DTRL motif of CFTR and anchor it to the actin cytoskeleton, maintaining its apical membrane localization.
- **Chaperones**: Hsp70, Hsp90, and their co-chaperones (e.g., Hdj-2, Aha1) facilitate CFTR folding. Aha1 is a co-chaperone that promotes ATPase activity of Hsp90 and has been shown to destabilize ΔF508-CFTR; inhibition of Aha1 is a potential therapeutic strategy.
- **E3 Ubiquitin Ligases**: CHIP, RNF185, and SYVN1 mediate the ubiquitination of CFTR, targeting it for proteasomal degradation [2, 3].
- **Deubiquitinating Enzymes**: USP10 and USP19 remove ubiquitin moieties from CFTR, rescuing it from degradation.
- **Kinases and Phosphatases**: PKA and PKC phosphorylate the R domain, while protein phosphatase 2A (PP2A) and PP2C dephosphorylate it, inactivating the channel.

```mermaid
sequenceDiagram
    participant GPCR as "GPCR (e.g., β2-AR)"
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA (Regulatory + Catalytic)"
    participant CFTR as "CFTR (Phosphorylated)"
    participant ATP as "ATP"
    participant NBDs as "NBD1/NBD2 Dimer"
    participant Pore as "Channel Pore"
    Note over GPCR, Pore: CFTR Activation Pathway
    GPCR->>AC: Ligand binding (e.g., epinephrine)
    AC->>cAMP: Converts ATP to cAMP
    cAMP->>PKA: Binds to regulatory subunits
    PKA->>PKA: Releases catalytic subunits
    PKA->>CFTR: Phosphorylates R domain
    CFTR->>CFTR: Conformational change (R domain displaced)
    ATP->>NBDs: Binds to NBD1 and NBD2
    NBDs->>NBDs: Dimerization
    NBDs->>Pore: Coupling to channel gate
    Pore->>Pore: Opens (Cl⁻ and HCO₃⁻ efflux)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Classification of CFTR Mutations

The CFTR gene is highly polymorphic, with over 2,000 variants identified to date. These variants are classified into six functional classes based on their molecular consequence [1, 3]:

- **Class I (Defective Protein Synthesis)**: Nonsense, frameshift, and splicing mutations that result in a truncated or absent protein. Examples: G542X, W1282X, R553X.
- **Class II (Defective Protein Processing)**: Mutations that cause misfolding and ER retention, leading to proteasomal degradation. The most common is F508del. Other examples: N1303K, G85E.
- **Class III (Defective Channel Regulation)**: Mutations that impair ATP binding or hydrolysis at the NBDs, preventing channel opening. Examples: G551D, G1244E, S1251N.
- **Class IV (Defective Channel Conductance)**: Mutations that alter the pore structure, reducing chloride conductance. Examples: R117H, R334W, R347P.
- **Class V (Reduced Protein Synthesis)**: Mutations that reduce the amount of functional CFTR protein, often due to splicing defects. Examples: 3849+10kb C>T, 2789+5G>A.
- **Class VI (Reduced Stability)**: Mutations that reduce the half-life of CFTR at the plasma membrane. Examples: Q1412X, c.120del23.

### 4.2 The F508del Mutation: A Paradigm of Class II Mutations

F508del is the most common CFTR mutation, accounting for approximately 70% of CF alleles worldwide. The mutation is a deletion of three nucleotides (CTT) at positions c.1521_1523, resulting in the loss of phenylalanine at position 508. The F508del mutation is associated with a severe CF phenotype, including pancreatic insufficiency, elevated sweat chloride (>60 mmol/L), and progressive obstructive lung disease [1, 2].

The prevalence of F508del varies among populations. It is most common in Northern European populations and is rare or absent in African and Asian populations. The severity of the F508del phenotype is modulated by genetic modifiers, including variants in the TGF-β, MBL2, and IFRD1 genes.

### 4.3 Gating Mutations (Class III) and Ivacaftor Responsiveness

Class III mutations, such as G551D, are characterized by normal protein processing and trafficking but defective channel gating. The G551D mutation is the second most common CFTR mutation, accounting for approximately 4–5% of CF alleles. The glycine at position 551 is located in the Walker A motif of NBD1, and its substitution with aspartate disrupts ATP binding and hydrolysis, preventing NBD dimerization and channel opening.

Ivacaftor (VX-770) is a CFTR potentiator that binds directly to the CFTR channel and increases the open probability (Po) of the channel. Ivacaftor was the first CFTR modulator approved by the FDA, initially for the treatment of CF patients with the G551D mutation. Mechanistic studies using purified, reconstituted CFTR in planar lipid bilayers demonstrated that ivacaftor opens the defective channel gate of G551D-CFTR in a phosphorylation-dependent but ATP-independent manner [3]. This finding was unexpected and suggested that ivacaftor can bypass the requirement for ATP binding and hydrolysis, directly stabilizing the open state of the channel.

### 4.4 CFTR-Related Disorders (CFTR-RDs)

Mutations in CFTR can cause a spectrum of disorders that are distinct from classic CF, collectively termed CFTR-related disorders. These conditions are typically associated with mild CFTR dysfunction, with residual channel activity of 10–50% of normal:

- **Congenital Bilateral Absence of the Vas Deferens (CBAVD)**: CBAVD is the most common CFTR-RD, accounting for ~2% of male infertility. Most men with CBAVD carry two CFTR mutations, but these are typically mild (e.g., R117H, 5T allele) and do not cause classic CF [1, 2, 3]. The 5T allele in the intron 8 splice acceptor site is a common variant associated with CBAVD; its pathogenicity is modulated by the length of the adjacent (TG)m repeat [1].
- **Idiopathic Chronic Pancreatitis**: CFTR mutations are found in 10–20% of patients with idiopathic chronic pancreatitis. The mechanism involves impaired bicarbonate secretion, leading to the precipitation of pancreatic enzymes and ductal obstruction [1, 2, 3]. The CFTR mutation/variant/haplotype interacts with tumor necrosis factor (TNF) promoter polymorphisms to modulate the risk of hyperlipidemic pancreatitis [3].
- **Allergic Bronchopulmonary Aspergillosis (ABPA)**: CFTR mutations are more frequent in patients with ABPA, a hypersensitivity reaction to Aspergillus fumigatus, suggesting that CFTR dysfunction predisposes to this condition [1, 2].
- **Primary Sclerosing Cholangitis (PSC)**: CFTR gene defects have been identified in a subset of patients with PSC, a chronic cholestatic liver disease [3].
- **Disseminated Bronchiectasis**: CFTR mutations are found in a small percentage of patients with non-CF bronchiectasis, particularly in Asian populations [1].

### 4.5 CFTR and Cancer Risk

Epidemiological studies have investigated the association between CFTR mutations and cancer risk:

- **Colorectal Cancer**: A large English population-based study found that individuals with CF have a significantly higher risk of developing colorectal cancer (CRC) compared to the general population. The risk was also elevated, albeit to a lesser extent, in carriers of CFTR mutations [3].
- **Pancreatic Adenocarcinoma**: CFTR mutations have been associated with an increased risk of pancreatic adenocarcinoma, particularly in individuals with a family history of the disease [1].
- **Lung Cancer**: A case-control study found that CFTR mutations may be associated with an increased risk of lung cancer, although the findings were not statistically significant [3].
- **Prostate Cancer**: In contrast, the CFTR 5T allele was found to be associated with a reduced risk of prostate cancer in a Chinese Han population, suggesting a protective effect [2].

The mechanisms linking CFTR dysfunction to cancer are not fully understood but may involve chronic inflammation, impaired immune surveillance, and altered cellular signaling pathways.

## 5. Host-Pathogen & Viral Interactions

### 5.1 CFTR and Bacterial Pathogens

The airway epithelium of CF patients is chronically colonized by a characteristic set of bacterial pathogens, including *[Pseudomonas aeruginosa](/knowledge/bacteria/gram-negative/pseudomonas-aeruginosa-multidrug-resistance-biofilms)*, *Staphylococcus aureus*, *Haemophilus influenzae*, and *Burkholderia cepacia* complex. The loss of CFTR function creates a permissive environment for bacterial colonization through several mechanisms:

- **Dehydrated Airway Surface Liquid (ASL)**: The loss of CFTR-mediated chloride and water secretion leads to a reduced ASL height, impairing mucociliary clearance and allowing bacteria to adhere to the airway epithelium.
- **Altered pH and Bicarbonate Secretion**: CFTR-mediated bicarbonate secretion is critical for maintaining the pH of the ASL and for the proper expansion of mucins. In CF, the reduced bicarbonate secretion leads to acidic ASL and abnormal mucus, which provides a niche for bacterial growth.
- **Impaired Bacterial Killing**: CFTR has been implicated in the internalization and killing of *P. aeruginosa* by airway epithelial cells. The F508del mutation impairs this process, leading to increased bacterial burden.

### 5.2 CFTR and Viral Infections

CF patients are also susceptible to severe viral infections, particularly with respiratory syncytial virus (RSV), influenza virus, and rhinovirus. CFTR dysfunction may impair antiviral immune responses, leading to prolonged and more severe infections. However, the direct interaction between viral proteins and CFTR is not well characterized.

### 5.3 CFTR and Fungal Pathogens

*Aspergillus fumigatus* is a common fungal pathogen in CF patients, causing ABPA. CFTR mutations are more frequent in patients with ABPA, suggesting a genetic predisposition [1, 2]. The mechanism may involve impaired mucociliary clearance and altered immune responses to fungal antigens.

### 5.4 CFTR and the Gut Microbiome

CFTR mutations have been shown to influence the composition of the gut microbiota. A study by Schippa et al. (2013) found that CFTR allelic variants relate to shifts in the faecal microbiota of CF patients, with a reduction in beneficial bacteria such as *Bifidobacterium* and an increase in potentially pathogenic bacteria [2]. This dysbiosis may contribute to the gastrointestinal manifestations of CF, including malabsorption and inflammation.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 CFTR Modulators

The development of CFTR modulators has transformed the treatment of CF. These small molecules are classified into two main categories:

- **Correctors**: Improve the folding and trafficking of mutant CFTR, particularly F508del-CFTR. Examples include lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445).
- **Potentiators**: Increase the open probability of CFTR channels at the cell surface. The prototypical potentiator is ivacaftor (VX-770).

### 6.2 FDA-Approved Combination Therapies

- **Ivacaftor (Kalydeco)**: Approved in 2012 for CF patients with the G551D mutation. Subsequently expanded to include other gating mutations (Class III) and the R117H mutation [3].
- **Lumacaftor/Ivacaftor (Orkambi)**: Approved in 2015 for CF patients homozygous for F508del. The combination of a corrector (lumacaftor) and a potentiator (ivacaftor) provides modest clinical benefit [1].
- **Tezacaftor/Ivacaftor (Symdeko)**: Approved in 2018. Tezacaftor is a next-generation corrector with improved tolerability compared to lumacaftor.
- **Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)**: Approved in 2019. This triple-combination therapy includes two correctors (elexacaftor and tezacaftor) with different binding sites on CFTR, resulting in a synergistic improvement in F508del-CFTR processing and function. Trikafta has demonstrated unprecedented clinical efficacy, with improvements in lung function (FEV1) of 10–14 percentage points and a 63% reduction in pulmonary exacerbations [1, 2].

### 6.3 Investigational Small Molecules

- **GLPG1837**: A novel potentiator that can open Class III mutant CFTR channels to a high extent. It is being investigated for the treatment of CF patients with gating mutations [3].
- **Readthrough Agents**: Compounds such as ataluren (PTC124) and gentamicin promote the readthrough of premature termination codons, allowing the synthesis of full-length CFTR protein in patients with Class I nonsense mutations [1].
- **Ubiquitylation Inhibitors**: Targeting the ubiquitin-proteasome system to rescue ΔF508-CFTR from degradation is a promising therapeutic strategy. Inhibitors of specific E3 ubiquitin ligases (e.g., CHIP, RNF185) or deubiquitinating enzymes (e.g., USP10) are being explored [3].

### 6.4 Gene Therapy and Gene Editing

Gene therapy approaches aim to deliver a functional copy of the CFTR gene to the airway epithelium:

- **Viral Vectors**: Adenoviral, adeno-associated viral (AAV), and lentiviral vectors have been used to deliver CFTR cDNA. Early clinical trials with adenoviral vectors demonstrated proof-of-concept but were limited by immune responses and transient expression [2, 3]. Lentiviral vectors have shown promise in animal models, with single-dose administration leading to sustained CFTR function [1].
- **Non-Viral Vectors**: Plasmid DNA and mRNA-based approaches have been explored. Intratracheal delivery of CFTR mRNA complexed with cationic lipids has been shown to restore CFTR function in vitro and in vivo [2, 3].
- **Gene Editing**: Zinc-finger nucleases (ZFNs), TALENs, and CRISPR/Cas9 have been used to correct the F508del mutation in patient-derived cells. ZFN-mediated homology-directed repair (HDR) has been demonstrated in CF airway epithelial cells [1]. More recently, CRISPR/Cas9-based approaches have been developed to target the CFTR locus [2].
- **Zinc Finger Protein Activation**: Targeted activation of endogenous CFTR using engineered zinc finger proteins delivered via mesenchymal stem cell exosomes has been shown to upregulate CFTR expression and function [1, 3].

### 6.5 Antisense Oligonucleotides (ASOs)

ASOs can be used to correct aberrant splicing of CFTR. For example, ASOs targeting the cryptic splice site created by the 3849+10kb C>T mutation have been shown to restore normal splicing and CFTR function [3]. ASOs can also be used to knock down the expression of negative regulators of CFTR, such as miR-145-5p [1].

### 6.6 Pharmacogenomic Considerations

The response to CFTR modulators is highly dependent on the specific CFTR mutation. In vitro studies using patient-derived cell models have been used to define the responsiveness of different CFTR variants to modulator therapy. The FDA has expanded the labels of CFTR modulators to include variants that show in vitro responsiveness, even if clinical data are limited [2, 3]. This approach has significantly expanded the number of CF patients eligible for modulator therapy.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| NCBI Gene | 1080 | https://www.ncbi.nlm.nih.gov/gene/1080 |
| Ensembl | ENSG00000001626 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000001626 |
| UniProt | P13569 | https://www.uniprot.org/uniprotkb/P13569 |
| RCSB PDB | 5UAK | https://www.rcsb.org/structure/5UAK |
| ClinVar | CFTR | https://www.ncbi.nlm.nih.gov/clinvar/?term=CFTR%5Bgene%5D |
| HGMD | CFTR | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFTR |
| CFTR2 (Clinical and Functional Translation of CFTR) | CFTR | https://cftr2.org/ |
| Gene Ontology (GO) | GO:0005247 (chloride channel activity); GO:0005254 (chloride channel complex); GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| STRING (Protein-Protein Interaction) | P13569 | https://string-db.org/network/9606.ENSP00000003084 |
| BioGRID | CFTR | https://thebiogrid.org/108196 |
| OMIM | 602421 (CFTR); 219700 (Cystic fibrosis) | https://www.omim.org/entry/602421 |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Tazi, M. F., Dakhlallah, D., Caution, K., Gerber, M. M., Chang, S.-W., Khalil, H., Kopp, B., Ahmed, A., Krause, K., Davis, I., Marsh, C., Lovett-Racke, A., Schlesinger, L., Cormet-Boyaka, E., & Amer, A. (2016). Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages. *Autophagy*. https://www.semanticscholar.org/paper/a27ae21197419bacb49fb28cad30c96a9acb2e4f

[2] Lipecka, J., Norez, C., Bensalem, N., Baudouin-Legros, M., Planelles, G., Becq, F., Edelman, A., & Davezac, N. (2006). Rescue of ΔF508-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) by Curcumin: Involvement of the Keratin 18 Network. *Journal of Pharmacology and Experimental Therapeutics*. https://www.semanticscholar.org/paper/50a5f55030a7a96e99550b110e1aed8af745108d

[3] Birch, R. J., Peckham, D., Wood, H., Quirke, P., Konstant-Hambling, R., Brownlee, K., Cosgriff, R., Consortium, G., Burr, N., & Downing, A. (2022). The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CF